Trial Profile
Multicenter, randomized, double-blind, placebo, parallel-group phase III clinical studies of recombinant human (rh) Apo2L/TRAIL in combination with vinorelbine and cispatin (NP) in patients with advanced NSCLC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2017
Price :
$35
*
At a glance
- Drugs Dulanermin (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- 14 Nov 2017 Results assessing efficacy and tolerability of first-line therapy with dulanermin + vinorelbine + cisplatin versus vinorelbine + cisplatin alone in patients with advanced non-small cell lung cancer, were published in the Investigational New Drugs.
- 03 Jun 2014 Initial results from a single study centre (n=26) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 26 Nov 2013 New trial record